Abnormal Liver Function Tests of Patients with Coronavirus Disease 2019 in Mainland China: A Systematic Review and Meta- Analysis

Authors

  • Shengliang Xin Department of Infectious Disease, Peking University First Hospital, Beijing, China
  • Jinghang Xu Department of Infectious Disease, Peking University First Hospital, Beijing, China
  • Yanyan Yu Department of Infectious Disease, Peking University First Hospital, Beijing, China

DOI:

https://doi.org/10.15403/jgld-2513

Keywords:

COVID-19, liver, laboratory test, meta-analysis

Abstract

Aims: Comparing the risk of abnormal liver function tests between severe and non-severe patients with coronavirus disease 2019 (COVID-19) by meta-analysis.

Methods: A literature search was conducted using the databases PubMed, Embase, and Cochrane Library. Odds ratios (ORs) and 95% confidence intervals (CIs) were pooled using fixed- or random-effects models. Publication bias was detected by the Harbord test.

Results: We included 8 articles comprising 7,467 COVID-19 patients. When compared between severe and non-severe COVID-19 patients, the pooled ORs of elevated alanine aminotransferase, aspartate aminotransferase, total bilirubin, and lactate dehydrogenase levels were 2.35 (95% CI 1.38-3.98), 3.21 (95% CI 2.59-3.98), 1.87 (95% CI 1.32-2.65), and 4.83 (95% CI 2.90-8.05), respectively.

Conclusions: The severity of COVID-19 is associated with liver damage, and can be a risk factor for abnormal liver function tests.

Published

2020-06-03

How to Cite

1.
Xin S, Xu J, Yu Y. Abnormal Liver Function Tests of Patients with Coronavirus Disease 2019 in Mainland China: A Systematic Review and Meta- Analysis. JGLD [Internet]. 2020 Jun. 3 [cited 2025 Jul. 1];29(2):219-26. Available from: https://www.jgld.ro/jgld/index.php/jgld/article/view/2513

Issue

Section

Systematic Review and Meta-Analysis